Platelet-Derived Growth Factor as a Therapeutic Target for Systemic Autoimmune Diseases
Some systemic rheumatic diseases and disorders, especially fibrotic and vascular disorders, are often refractory to corticosteroid therapy. Recently, ever accumulating evidence suggests that platelet-derived growth factor (PDGF) is involved in those refractory diseases. Imatinib mesylate inhibits th...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2007-01-01
|
| Series: | Drug Target Insights |
| Online Access: | https://doi.org/10.1177/117739280700200006 |
| _version_ | 1818259413957345280 |
|---|---|
| author | Hideto Kameda Miyuki Suzuki Tsutomu Takeuchi |
| author_facet | Hideto Kameda Miyuki Suzuki Tsutomu Takeuchi |
| author_sort | Hideto Kameda |
| collection | DOAJ |
| description | Some systemic rheumatic diseases and disorders, especially fibrotic and vascular disorders, are often refractory to corticosteroid therapy. Recently, ever accumulating evidence suggests that platelet-derived growth factor (PDGF) is involved in those refractory diseases. Imatinib mesylate inhibits the activation of PDGF receptor as well as c-Abl, Bcr-Abl and c-Kit tyrosine kinases. It has therefore been widely used for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. Imatinib effectively suppresses the activation and proliferation of fibroblasts, mesangial cells and smooth muscle cells both in vitro and in vivo. Additionally, it has recently been reported that some patients with rheumatoid arthritis or idiopathic pulmonary arterial hypertension demonstrated a good clinical response to imatinib therapy. Imatinib may therefore overcome the limitations of current therapeutic strategy with corticosteroids and immunosuppressive agents for refractory diseases, such as systemic sclerosis and interstitial lung diseases, without clinical intolerability. |
| first_indexed | 2024-12-12T18:15:03Z |
| format | Article |
| id | doaj.art-88d54a1cb8e44d5e928a857e4049ba41 |
| institution | Directory Open Access Journal |
| issn | 1177-3928 |
| language | English |
| last_indexed | 2024-12-12T18:15:03Z |
| publishDate | 2007-01-01 |
| publisher | AboutScience Srl |
| record_format | Article |
| series | Drug Target Insights |
| spelling | doaj.art-88d54a1cb8e44d5e928a857e4049ba412022-12-22T00:16:17ZengAboutScience SrlDrug Target Insights1177-39282007-01-01210.1177/117739280700200006Platelet-Derived Growth Factor as a Therapeutic Target for Systemic Autoimmune DiseasesHideto Kameda0Miyuki Suzuki1Tsutomu Takeuchi2Division of Rheumatology/Clinical Immunology, Department of Internal Medicine, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan.Division of Rheumatology/Clinical Immunology, Department of Internal Medicine, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan.Division of Rheumatology/Clinical Immunology, Department of Internal Medicine, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan.Some systemic rheumatic diseases and disorders, especially fibrotic and vascular disorders, are often refractory to corticosteroid therapy. Recently, ever accumulating evidence suggests that platelet-derived growth factor (PDGF) is involved in those refractory diseases. Imatinib mesylate inhibits the activation of PDGF receptor as well as c-Abl, Bcr-Abl and c-Kit tyrosine kinases. It has therefore been widely used for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. Imatinib effectively suppresses the activation and proliferation of fibroblasts, mesangial cells and smooth muscle cells both in vitro and in vivo. Additionally, it has recently been reported that some patients with rheumatoid arthritis or idiopathic pulmonary arterial hypertension demonstrated a good clinical response to imatinib therapy. Imatinib may therefore overcome the limitations of current therapeutic strategy with corticosteroids and immunosuppressive agents for refractory diseases, such as systemic sclerosis and interstitial lung diseases, without clinical intolerability.https://doi.org/10.1177/117739280700200006 |
| spellingShingle | Hideto Kameda Miyuki Suzuki Tsutomu Takeuchi Platelet-Derived Growth Factor as a Therapeutic Target for Systemic Autoimmune Diseases Drug Target Insights |
| title | Platelet-Derived Growth Factor as a Therapeutic Target for Systemic Autoimmune Diseases |
| title_full | Platelet-Derived Growth Factor as a Therapeutic Target for Systemic Autoimmune Diseases |
| title_fullStr | Platelet-Derived Growth Factor as a Therapeutic Target for Systemic Autoimmune Diseases |
| title_full_unstemmed | Platelet-Derived Growth Factor as a Therapeutic Target for Systemic Autoimmune Diseases |
| title_short | Platelet-Derived Growth Factor as a Therapeutic Target for Systemic Autoimmune Diseases |
| title_sort | platelet derived growth factor as a therapeutic target for systemic autoimmune diseases |
| url | https://doi.org/10.1177/117739280700200006 |
| work_keys_str_mv | AT hidetokameda plateletderivedgrowthfactorasatherapeutictargetforsystemicautoimmunediseases AT miyukisuzuki plateletderivedgrowthfactorasatherapeutictargetforsystemicautoimmunediseases AT tsutomutakeuchi plateletderivedgrowthfactorasatherapeutictargetforsystemicautoimmunediseases |